B
Bruce T. Adornato
Researcher at Stanford University
Publications - 15
Citations - 1624
Bruce T. Adornato is an academic researcher from Stanford University. The author has contributed to research in topics: Randomized controlled trial & Placebo. The author has an hindex of 12, co-authored 15 publications receiving 1577 citations. Previous affiliations of Bruce T. Adornato include Santa Clara Valley Medical Center.
Papers
More filters
Journal ArticleDOI
The effect of systemically administered recombinant human nerve growth factor in healthy human subjects
Brent G. Petty,David R. Cornblath,Bruce T. Adornato,Vinay Chaudhry,Charles Flexner,Matthew Wachsman,Dominick Sinicropi,Louis E. Burton,Stephen J. Peroutka +8 more
TL;DR: Results indicate that systemically administered rhNGF exerts a characteristic and reproducible biological effect in healthy subjects at very low doses and in a dose‐dependent manner.
Journal ArticleDOI
A phase II trial of nerve growth factor for sensory neuropathy associated with HIV infection
Justin C. McArthur,Constantin T. Yiannoutsos,David M. Simpson,Bruce T. Adornato,Elyse J. Singer,Harry Hollander,Camillo Marra,Michael Rubin,Bruce A. Cohen,Tarvez Tucker,Bradford A. Navia,Giovanni Schifitto,David Katzenstein,C. A. Rask,Lawrence Zaborski,Mary E. Smith,S. Shriver,Linda Millar,David B. Clifford +18 more
TL;DR: A positive effect of recombinant human nerve growth factor on neuropathic pain and pin sensitivity in HIV-associated sensory neuropathy was found and rhNGF was safe and well tolerated, but injection site pain was frequent.
Journal ArticleDOI
Recombinant human nerve growth factor in the treatment of diabetic polyneuropathy. NGF Study Group.
TL;DR: In this article, the effects of recombinant human nerve growth factor in patients with diabetic polyneuropathy were evaluated and the results showed that it appeared to be safe and showed preliminary evidence of efficacy.
Journal ArticleDOI
Botulinum toxin type B: A double-blind, placebo-controlled, safety and efficacy study in cervical dystonia
Mark F. Lew,Bruce T. Adornato,Drake D. Duane,Dennis D. Dykstra,Stewart A. Factor,Janice M. Massey,Mitchell F. Brin,Joseph Jankovic,Robert L. Rodnitzky,Carlos Singer,Michael R. Swenson,Daniel Tarsy,J. J. Murray,M. Koller,J. D. Wallace +14 more
TL;DR: BotB is safe, well tolerated, and efficacious in the treatment of cervical dystonia at the doses tested and a statistically significant treatment effect and a dose response.
Journal ArticleDOI
A comparison of Asian and white patients with obstructive sleep apnea syndrome.
Kasey K. Li,Nelson B. Powell,Clete A. Kushida,Robert Riley,Bruce T. Adornato,Christian Guilleminault +5 more
TL;DR: To evaluate the possible differences between Asian and white patients with obstructive sleep apnea syndrome, a large number of patients with the condition are classified as either white or Asian.